Press "Enter" to skip to content

LIDDS develops its own proprietary product for intratumoral immunotherapy – Freedom to operate analysis done for the TLR9-agonist project – GlobeNewswire

admin 0

LIDDS develops its own proprietary product for intratumoral immunotherapy – Freedom to operate analysis done for the TLR9-agonist project  GlobeNewswire

LIDDS has an ongoing preclinical development program based on a clinical stage TLR9 agonist. The objective is to use a NanoZolid® formulation with the TLR9 …

“lymphoma cancer” – Google News

(Visited 5 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *